Sutro Biopharma Inc
NASDAQ:STRO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sambhaav Media Ltd
NSE:SAMBHAAV
|
IN |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (4.1), the stock would be worth $-32.72 (192% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -4.4 | $35.53 |
0%
|
| 3-Year Average | 4.1 | $-32.72 |
-192%
|
| 5-Year Average | 4.8 | $-38.53 |
-208%
|
| Industry Average | 4.6 | $-36.9 |
-204%
|
| Country Average | 2.5 | $-20.26 |
-157%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
Sutro Biopharma Inc
NASDAQ:STRO
|
588.7m USD | -4.4 | -3.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -164 720.7 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
354.5B USD | -108.4 | 84.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
186.5B USD | 21.5 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
164.9B USD | 7.3 | 19.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
111.2B USD | 6 | 28.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -5 465.3 | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 2.5 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42B EUR | 6.7 | 37.9 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 18.2 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.3B AUD | 2.3 | 30.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.5 |
| Median | 2.5 |
| 70th Percentile | 4.8 |
| Max | 147 580.5 |
Other Multiples
Sutro Biopharma Inc
Glance View
Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. The company is headquartered in South San Francisco, California and currently employs 224 full-time employees. The company went IPO on 2018-09-27. The company is focused on deploying its integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF, to create a variety of protein therapeutics, initially for cancer. The company is engaged in designing therapeutics using potent modalities, including cytokine-based therapeutics, immuno-oncology agents, antibody-drug conjugates (ADCs) and bispecific antibodies that are directed against clinically validated targets. Its product candidate includes STRO-002 and STRO-001. STRO-002, is an ADC directed against folate receptor-alpha, for patients with FolRα-expressing cancers, such as ovarian and endometrial cancers. STRO-001, is an ADC directed against CD74, for patients with B-cell malignancies, such as multiple myeloma and non-Hodgkin lymphoma. Its product candidates are designed and optimized for therapeutic index by placing linker-warheads at specific locations within the antibody.
